United States

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, currently in Phase II clinical trial for COVID-19 treatment. The company also develops other antiviral drugs for dengue, HCV, and other RNA viral infections. Atea has a license agreement with Merck & Co for the development and commercialization of ruzasvir for HCV treatment. The company was founded in 2012 and is based in Boston, Massachusetts.

Google

مدیر محصول

دانشمند داده

Atea Pharmaceuticals

Atea Pharmaceuticals مشاغل باز

آیا آماده ارتقای شغلی خود هستید؟ این نقش‌های باز در Atea Pharmaceuticals را بررسی کنید.